The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
930
September 2, 1994
View Complete Issue         Table of Contents 2019 
Acrivastine/Pseudoephedrine (Semprex-D) for Seasonal Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Acrivastine/Pseudoephedrine (Semprex-D) for Seasonal Allergic Rhinitis
September 2, 1994 (Issue: 930)
Acrivastine/Pseudoephedrine (Semprex-D) for Seasonal Allergic Rhinitis (Burroughs-Wellcome), a combination of acrivastine with pseudoephedrine hydrochloride, has been approved by the US Food and Drug Administration for treatment of seasonal...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Acrivastine/Pseudoephedrine (Semprex-D) for Seasonal Allergic Rhinitis
Article code: 930b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.